Zenith Drugs Limited (NSE:ZENITHDRUG)
India · Delayed Price · Currency is INR 41.65
+0.55 (1.34%)
Jun 17, 2026, 3:27 PM IST
Zenith Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,712 | 1,333 | 1,316 | 1,145 | 916.55 |
Other Revenue | 51.01 | - | -0 | -0 | 0 |
| 1,763 | 1,333 | 1,316 | 1,145 | 916.55 | |
Revenue Growth (YoY) | 32.25% | 1.29% | 14.93% | 24.95% | 24.87% |
Cost of Revenue | 1,226 | 876.42 | 856.6 | 783.17 | 727.11 |
Gross Profit | 537.68 | 456.78 | 459.6 | 362.02 | 189.44 |
Selling, General & Admin | 91.11 | 79.72 | 66 | 52.17 | 38.44 |
Other Operating Expenses | 273.95 | 235.26 | 213.24 | 210.8 | 82.69 |
Operating Expenses | 425.54 | 344.65 | 292.25 | 276.02 | 134.39 |
Operating Income | 112.14 | 112.13 | 167.35 | 86 | 55.05 |
Interest Expense | -56.11 | -21.83 | -20.01 | -11.48 | -18.18 |
Interest & Investment Income | - | 19.59 | 10.83 | 1.6 | 5.22 |
Other Non Operating Income (Expenses) | - | -15.28 | -9.8 | -10.18 | -2.93 |
EBT Excluding Unusual Items | 56.03 | 94.61 | 148.37 | 65.95 | 39.17 |
Gain (Loss) on Sale of Investments | - | 0.46 | - | - | - |
Other Unusual Items | -2.15 | -2.46 | -15.45 | - | 4.27 |
Pretax Income | 53.87 | 92.61 | 132.92 | 66.57 | 44.06 |
Income Tax Expense | 14.45 | 21 | 37.55 | 17.76 | 12.77 |
Earnings From Continuing Operations | 39.43 | 71.61 | 95.37 | 48.8 | 31.29 |
Minority Interest in Earnings | - | - | - | 0 | 0.1 |
Net Income | 39.43 | 71.61 | 95.37 | 48.81 | 31.38 |
Net Income to Common | 39.43 | 71.61 | 95.37 | 48.81 | 31.38 |
Net Income Growth | -44.94% | -24.92% | 95.40% | 55.53% | 3.60% |
Shares Outstanding (Basic) | 17 | 17 | 17 | 12 | 12 |
Shares Outstanding (Diluted) | 17 | 17 | 17 | 12 | 12 |
Shares Change (YoY) | -0.04% | - | 42.91% | - | - |
EPS (Basic) | 2.30 | 4.18 | 5.56 | 4.07 | 2.62 |
EPS (Diluted) | 2.30 | 4.18 | 5.56 | 4.07 | 2.62 |
EPS Growth | -44.92% | -24.90% | 36.70% | 55.53% | 3.60% |
Free Cash Flow | -8.41 | -375.79 | -211.7 | -103.43 | -0.89 |
Free Cash Flow Per Share | -0.49 | -21.91 | -12.35 | -8.62 | -0.07 |
Dividend Per Share | - | - | 0.500 | - | - |
Gross Margin | 30.49% | 34.26% | 34.92% | 31.61% | 20.67% |
Operating Margin | 6.36% | 8.41% | 12.71% | 7.51% | 6.01% |
Profit Margin | 2.24% | 5.37% | 7.25% | 4.26% | 3.42% |
Free Cash Flow Margin | -0.48% | -28.19% | -16.08% | -9.03% | -0.10% |
EBITDA | 172.62 | 141.8 | 180.37 | 99.06 | 68.31 |
EBITDA Margin | 9.79% | 10.64% | 13.70% | 8.65% | 7.45% |
D&A For EBITDA | 60.48 | 29.66 | 13.02 | 13.05 | 13.26 |
EBIT | 112.14 | 112.13 | 167.35 | 86 | 55.05 |
EBIT Margin | 6.36% | 8.41% | 12.71% | 7.51% | 6.01% |
Effective Tax Rate | 26.82% | 22.68% | 28.25% | 26.68% | 28.99% |
Revenue as Reported | 1,763 | 1,359 | 1,337 | 1,158 | 926.66 |
Advertising Expenses | - | 4.97 | 3.8 | 1.85 | 1.26 |